10th February 2022

Analysts back biotech & healthcare trusts as sector struggles

Biotechnology stocks have plummeted since pandemic peaks and the majority of investment trusts that focus on the sector have fallen, unsurprisingly, to discounts. However, analysts at Stifel have said this provides a “fertile environment for active funds to pick through the wreckage” and the trusts themselves are worth another look. Meanwhile, Berenberg say the healthcare peers also should not be ignored.